Use fundamental data analysis to confirm all available indicators of Virtus LifeSci Biotech to find out if markets are presently mispricing the entity. We found ten available drivers for Virtus LifeSci Biotech Clinical Trls ETF which can be compared to its competition. Please use Virtus LifeSci Total Asset, and the relationship between Price to Sales and Three Year Return to make a decision on weather Virtus LifeSci Biotech is priced fairly. Use Virtus LifeSci to protect against small markets fluctuations. The etf experiences normal downward trend and little activity. Check odds of Virtus LifeSci to be traded at $33.85 in 30 days
Virtus LifeSci Company SummaryVirtus LifeSci competes with iShares US, JHancock Multifactor, ProShares Decline, SPDR Kensho, and CNSF. Virtus LifeSci Biotech Clinical Trls ETF is USA based ETF administrated by Virtus ETF Solutions LLC. The ETF is issued and managed by BioShares, and composed of 85 constituents. The fund currently manages 54.7 M in total asset with 0.79 percent management fee and under 0.79 percent of total fund expense. Virtus LifeSci Biotech Clinical Trials ETF invests mostly in Developed Markets around North America and is publically traded since December 17, 2014.
Virtus LifeSci Price to Sales vs Price to Earning
Virtus LifeSci Biotech Clinical Trls ETF is the top ETF in price to sales as compared to similar ETFs. It is the top ETF in price to earning as compared to similar ETFs reporting about 20.04 of Price to Earning per Price to Sales.